Feraheme: Phase III started

AMAG began a double-blind, U.S. Phase III trial to compare 1.02 g IV Feraheme vs. 1.5 g IV Injectafer ferric carboxymaltose in about 2,000 patients. Feraheme is marketed in the U.S. to treat iron def...